SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SMX (Security Matters) Plc is a holding company, which engages in the provision of authentication solutions. It offers brand protection, authentication, and track and trace technology. The company was founded by Haggai Alon on July 1, 2022 and is headquartered in Dublin, Ireland.

SMX (Security Matters) Plc

SMX (Security Matters) PLC

SMX is trending following news of strengthening its balance sheet by converting convertible notes, eliminating corporate-level indebtedness and potential equity overhang. This development has ignited fervent community discussion, with many anticipating a massive short squeeze due to the perceived low float and high short interest. However, others remain cautious, recalling the stock's history of extreme volatility and sharp price corrections, debating if this marks a significant rebound or another speculative cycle.

Ondas Holdings, Inc. engages in the development, marketing, and sale of wireless radio systems for secure, wide area mission-critical business-to-business networks. It operates through the Ondas Networks and Ondas Autonomous Systems segments. The Ondas Networks segment provides wireless connectivity solutions enabling mission-critical Industrial Internet applications and services. The Ondas Autonomous Systems segment designs, develops, and markets commercial drone solutions via the Optimus System and Scout System. The company was founded on December 22, 2014 and is headquartered in West Palm Beach, FL.

Ondas Holdings Inc

Ondas Holdings is generating significant buzz as its subsidiary is reported to be a prime contractor for a major border security initiative, fueling strong community discussion around its autonomous drone and counter-UAS capabilities. Investors are actively anticipating substantial growth, viewing the company as a key player in the expanding global defense sector, especially with broad tailwinds from increased military spending and drone technology adoption.

Aclarion, Inc. is a healthcare technology company, which engages in the provision of Magnetic Resonance Spectroscopy (MRS), and a proprietary biomarker to optimize clinical treatments. It utilizes Artificial Intelligence to assist in quality control processes that flag spectroscopy data indicative of a poor MRS study. It offers NOCISCAN Suite, a revolutionary software suite that works with existing high field Magnetic Resonance systems and Magnetic Resonance Spectroscopy pulse sequence packages using an optimized protocol to conduct MRS exams of lumbar discs. The company was founded by James C. Peacock, David S. Bradford, and Jeffrey Lotz in 2008 and is headquartered in Broomfield, CO.

Aclarion Inc

Aclarion Inc. is trending after announcing triple-digit growth for its AI back pain platform, a strong cash position, and no debt, extending its cash runway into 2027. The community is buzzing with speculation about a potential short squeeze, given its low float and perceived high short interest, drawing comparisons to past high-flying small-cap runners. Many investors are eyeing significant upside, believing the stock is undervalued based on its fundamentals and the potential of its diagnostic technology.

flyExclusive, Inc. engages in owning and operating jet aircraft for private jet passengers. It manages all aspects of the customer experience, in-house maintenance, repair, and overhaul services, including paint, interiors, and avionics capabilities. The company was founded by Thomas James Segrave, Jr. in 2015 and is headquartered in Kinston, NC.

flyExclusive Inc. - Ordinary Shares - Class A

flyExclusive Inc. is actively trending following a significant partnership with Starlink, positioning the company as an authorized dealer and installer for SpaceX's high-speed in-flight connectivity on private jets. This development has fueled widespread community discussion around its potential to drive a substantial short squeeze and future price appreciation, though some traders note existing volatility.

Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. It offers tri-specific Nanobody, Sonelokimab to address significant unmet needs in inflammatory skin and joint diseases. The company was founded by Kristian Reich, Jorge Santos da Silva, and Arnout Ploos van Amstel in 2021 and is headquartered in Zug, Switzerland.

MoonLake Immunotherapeutics - Ordinary Shares - Class A

MoonLake Immunotherapeutics

MoonLake Immunotherapeutics is trending after receiving positive FDA feedback, confirming no additional clinical trials are needed for its lead drug, sonelokimab, to support a Biologics License Application for hidradenitis suppurativa. This crucial regulatory clarity is fueling investor optimism, with the community viewing it as a significant de-risking event for the asset. Many anticipate substantial analyst price target upgrades and renewed speculation about a potential buyout, particularly from Merck, given the drug's market opportunity.

Apple, Inc. engages in the design, manufacture, and sale of smartphones, personal computers, tablets, wearables and accessories, and other varieties of related services. It operates through the following geographical segments: Americas, Europe, Greater China, Japan, and Rest of Asia Pacific. The Americas segment includes North and South America. The Europe segment consists of European countries, as well as India, the Middle East, and Africa. The Greater China segment comprises China, Hong Kong, and Taiwan. The Rest of Asia Pacific segment includes Australia and Asian countries. Its products and services include iPhone, Mac, iPad, AirPods, Apple TV, Apple Watch, Beats products, AppleCare, iCloud, digital content stores, streaming, and licensing services. The company was founded by Steven Paul Jobs, Ronald Gerald Wayne, and Stephen G. Wozniak in April 1976 and is headquartered in Cupertino, CA.

Apple Inc

Apple is trending after experiencing a multi-day pullback, with investors keenly debating whether the stock is ripe for a bounce due to oversold technicals. While many anticipate a rebound, others express caution, highlighting a perceived lack of immediate AI catalysts compared to peers and Apple's recent market capitalization shift behind Alphabet. This dynamic has created a split in community sentiment, ranging from aggressive dip-buying to continued bearishness.

CorMedix, Inc. is a pharmaceutical and medical device company, which engages in the development and commercialization of therapeutic products for the prevention and treatment of diseases and conditions. The company was founded by Antony E. Pfaffle on July 28, 2006 and is headquartered in Berkeley Heights, NJ.

CorMedix Inc

CorMedix is trending due to preliminary financial guidance for upcoming years projecting a decrease in DefenCath revenue, leading to a sharp market reaction and significant community debate. While many investors express frustration and question management's approach, others argue that the revenue adjustments for the post-TDAPA period were anticipated and the sell-off is an overreaction. The conversation highlights the ongoing strategic importance of the company's diversified portfolio and pipeline assets like REZZAYO, alongside discussions of potential short squeeze dynamics.

Serve Robotics, Inc. engages in providing self-driving delivery. It designs, develops, and operates zero-emissions robots that serve people in public spaces, starting with food delivery. The company was founded by Ali Kashani, Dmitry Demeshchuk and MJ Burk Chun in 2017 and is headquartered in Redwood City, CA.

Serve Robotics Inc

Serve Robotics (SERV) is experiencing significant buzz following endorsements from NVIDIA CEO Jensen Huang and Wedbush analyst Dan Ives, coupled with reports that the Trump administration is considering an executive order to boost the robotics industry. The community is actively discussing the company's rapidly expanding autonomous delivery fleet and partnerships with Uber Eats and DoorDash, anticipating a potential short squeeze fueled by high short interest within the burgeoning physical AI sector.

Ford Motor Co. engages in the manufacture, distribution, and sale of automobiles. It operates through the following segments: Ford Blue, Ford Model E, Ford Pro, Ford Next, Ford Credit, and Corporate Other. The Ford Blue, Ford Model E, and Ford Pro segment includes the sale of Ford and Lincoln vehicles, service parts, and accessories, together with the associated costs to develop, manufacture, distribute, and service the vehicles, parts, and accessories. The Ford Next segment is involved in the expenses and investments for emerging business initiatives aimed at creating value for Ford in vehicle-adjacent market segments. The Ford Credit segment consists of the Ford Credit business on a consolidated basis, which is primarily vehicle-related financing and leasing activities. The Corporate Other segment refers to corporate governance expenses, past service pension and OPEB income and expense, interest income and gains and losses from cash, cash equivalents, and marketable securities, and foreign exchange derivatives gains, and losses associated with intercompany lending. The company was founded by Henry Ford on June 16, 1903 and is headquartered in Dearborn, MI.

Ford Motor Co.

Ford Motor Co

Ford is trending due to a significant strategic pivot, exiting unprofitable large EV programs while doubling down on hybrids and affordable future electric vehicles, a move analysts like Piper Sandler are upgrading as a path to improved profitability. This re-focus, alongside strong overall sales driven by trucks and SUVs, is sparking community discussion about Ford's pragmatic adaptation to market demand, with some anticipating potential short squeeze dynamics despite a substantial write-down related to its past EV investments.

MannKind Corp. is a biopharmaceutical company, which focuses on the development and commercialization of innovative therapeutic products and devices to address serious unmet medical needs for those living with endocrine and orphan lung diseases. Its products and pipeline include Afrezza, Pediatric Afrezza, V-Go, Tyvaso DPI, MNKD-101, MNKD-201, MNKD-301, and MNKD-501. The company was founded by Alfred E. Mann on February 14, 1991 and is headquartered in Danbury, CT.

Mannkind Corp

Mannkind is notably trending following a business update highlighting a record revenue quarter and anticipation of multiple upcoming FDA decisions for its Afrezza and FUROSCIX products. While investors are enthusiastic about future growth catalysts and M&A speculation, there's ongoing community debate regarding past stock performance and insider share transactions.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

$EA Electronic Arts (EA) is expected to close its $55 billion leveraged buyout by a consortium led by Saudi Arabia&#39;s Public Investment Fund (PIF), Silver Lake, and Affinity Partners in Q1 of EA&#39;s fiscal year 2027 (FY27), which spans January to March 2026 and ends around March 31, 2026. 
 
The deal values EA at $210 per share, funded by ~$36 billion in equity (including PIF&#39;s rollover of its 9.9% stake) and $20 billion in debt from JPMorgan, marking the largest leveraged buyout ever.

StockTwits Web

Electronic Arts, Inc.

 Electronic Arts (EA) is expected to close its $55 billion leveraged buyout by a consortium led by Saudi Arabia's Public Investment Fund (PIF), Silver Lake, and Affinity Partners in Q1 of EA's fiscal year 2027 (FY27), which spans January to March 2026 and ends around March 31, 2026. 
 
The deal values EA at $210 per share, funded by ~$36 billion in equity (including PIF's rollover of its 9.9% stake) and $20 billion in debt from JPMorgan, marking the largest leveraged buyout ever.